These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22885677)

  • 1. Correlation among the toxicity profiling (28-days repeated oral dose toxicity), toxicokinetics and tissue distribution data of ulifloxacin, the active metabolite of prulifloxacin in Wistar albino rats.
    Nandi U; Roy B; Das AK; Pal TK
    Environ Toxicol Pharmacol; 2012 Sep; 34(2):588-607. PubMed ID: 22885677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of orally administered prulifloxacin into human prostate tissue.
    Giberti C; Gallo F; Rosignoli MT; Ruggieri A; Barattè S; Picollo R; Dionisio P
    Clin Drug Investig; 2009; 29(1):27-34. PubMed ID: 19067472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations.
    Gorlero F; Lorenzi P; Rosignoli MT; Picollo R; Ruggieri A; Barattè S; Dionisio P
    Drugs R D; 2007; 8(6):373-81. PubMed ID: 17963428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetration of orally administered prulifloxacin into human lung tissue.
    Concia E; Allegranzi B; Ciottoli GB; Orticelli G; Marchetti M; Dionisio P
    Clin Pharmacokinet; 2005; 44(12):1287-94. PubMed ID: 16372826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a liquid chromatography-tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: application to toxicokinetic study.
    Roy B; Choudhury H; Das A; Das AK; Pal TK
    Biomed Chromatogr; 2011 Aug; 25(8):890-901. PubMed ID: 21154639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery.
    De Benedetto M; Passali D; Tomacelli G; Ruggieri A; Rosignoli MT; Picollo R; Bellussi L; Dionisio P
    J Chemother; 2012 Feb; 24(1):26-31. PubMed ID: 22546721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment.
    Tellone V; Coppola P; Ammendola M; Di Loreto G; Picollo R; Del Vecchio A; Comandini A; Garofolo F; Tongiani S
    Drugs R D; 2018 Sep; 18(3):237-245. PubMed ID: 30151791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry.
    Guo L; Qi M; Jin X; Wang P; Zhao H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Mar; 832(2):280-5. PubMed ID: 16490405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study.
    Rosignoli MT; Di Loreto G; Dionisio P
    Clin Drug Investig; 2010; 30(1):5-14. PubMed ID: 19995094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Single-dose toxicity studies of prulifloxacin (NM441) in mice, rats and dogs and the active metabolite (NM394) in rats].
    Shimazu H; Ishikawa Y; Nishiguchi Y; Yoshida M; Iwakura K; Sumi N; Shindo Y
    J Toxicol Sci; 1996 Jun; 21 Suppl 1():33-44. PubMed ID: 8709168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats.
    Yagi Y; Aoki M; Iguchi M; Shibasaki S; Kurosawa T; Kato Y; Tsuji A
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):350-7. PubMed ID: 17965518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prulifloxacin.
    Keam SJ; Perry CM
    Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of ulifloxacin, the active metabolite of prulifloxacin, in human plasma by a 96-well format solid-phase extraction and capillary zone electrophoresis.
    Zhang L; Wen J; Pan Y; Li Z; Fan G; Wu Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Sep; 872(1-2):172-6. PubMed ID: 18706872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A 4-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test].
    Nishimura N; Fukuda K; Yamazaki S; Tamura K; Shindo Y; Iwakura K; Sumi N
    J Toxicol Sci; 1996 Jun; 21 Suppl 1():45-70. PubMed ID: 8709169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin.
    Montanari MP; Ferrante L; Tili E; Cochetti I; Rossi V; Varaldo PE
    J Chemother; 2005 Apr; 17(2):138-42. PubMed ID: 15920898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):285-92. PubMed ID: 9105547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and twenty-eight days repeated oral dose toxicity study of besifloxacin in Wistar albino rats.
    Roy B; Nandi U; Das A; Pal TK
    Environ Toxicol Pharmacol; 2011 Jul; 32(1):82-101. PubMed ID: 21787734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active uptake of ulifloxacin from plasma to lung that controls its concentration in epithelial lining fluid.
    Aoki M; Iguchi M; Hayashi H; Shibasaki S; Kurosawa T; Hayashi M
    Biol Pharm Bull; 2009 Jun; 32(6):1095-100. PubMed ID: 19483322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of Prulifloxacin in human aqueous humour following oral administration.
    Cagini C; Fiore T; Piccinellli F; Bartolini A; Riccitelli F; Pellegrino RM
    Acta Ophthalmol; 2012 Dec; 90(8):e661-2. PubMed ID: 22512865
    [No Abstract]   [Full Text] [Related]  

  • 20. Twenty-eight days repeated oral dose toxicity study of gemifloxacin in Wistar albino rats.
    Roy B; Sarkar AK; Sengupta P; Dey G; Das A; Pal TK
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):196-207. PubMed ID: 20580917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.